The PHOEBE study, which investigated the efficacy of pyrotinib or lapatinib plus capecitabine in the second‐line treatment for HER2‐positive metastatic breast cancer, presented additional analyses of the trastuzumab‐resistant subgroup at the San Antonio Breast Cancer Symposium in 2021. This evidence concerns the gene ERBB2 and breast cancer.